This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
A 2006 US government study of hospital emergency department (ED) visits found that sedative-hypnotics were the most frequently implicated pharmaceutical drug in visits, with benzodiazepines accounting for the majority of these. Clonazepam was the second most frequently implicated benzodiazepine in ED visits. Alcohol alone was responsible for over twice as many ED visits as clonazepam in the same study. The study examined the number of times the non-medical use of certain drugs was implicated in an ED visit. The criteria for non-medical use in this study were purposefully broad, and included, for example, drug abuse, accidental or intentional overdose, or adverse reactions resulting from legitimate use of the medication.
Merck & Co. adapted the 1936 laboratory-scale synthesis, allowing them to manufacture thiamine in Rahway in 1937. However, an alternative route using the intermediate Grewe diamine (5-(aminomethyl)-2-methyl-4-pyrimidinamine), first published in 1937, was investigated by Hoffman La Roche and competitive manufacturing processes followed. Efficient routes to the diamine have continued to be of interest. In the European Economic Area, thiamine is registered under REACH regulation and between 100 and 1,000 tonnes per annum are manufactured or imported there.
"I believe that all the power of the supreme being is not enough to liberate that despicable country (Peru): only Bolívar, supported by force, can do it." It is also known that San Martín wanted the disputed territory of Upper Peru, administered since 1810 by the Viceroyalty of Peru, to be handed over to the United Provinces of the Río de la Plata, which, although it would be somewhat predictable on his part (because it was an Argentine) in the exercise of a realpolitik, on the other hand it would be a sign of anti-Peruvianism on his part in the face of vague promises that he made to warlords, like Andrés de Santa Cruz, over the territory. Given this, he was allegedly accused of being dishonest with his ambiguous promises that he gave to Peruvian politicians who supported his government, since the Protectorate of San Martín de facto controlled the Atacama Party and was also claiming part of the territories of the current La Paz and Pando. That ended up generating a climate of mistrust, where the praises and praise of the Peruvians to the Liberator would have been apparent, in the midst of hostilities towards the Argentine caudillo. In the secret session of the Peruvian Congress, on September 27, 1822, suspicion and fear were expressed that San Martín tried to seize the provinces of Upper Peru, Arequipa and Cuzco.
== External links == Cytogenetic Directory Cytogenetics Resources Archived 2017-05-26 at the Wayback Machine Human Cytogenetics - Chromosomes and Karyotypes Association for Genetic Technologists Association of Clinical Cytogeneticists Archived 2000-01-17 at the Wayback Machine Gladwin Medical Blog Archived 2006-11-08 at the Wayback Machine Cytogenetics - Technologies, markets and companies Cytogenetics-methods-and-trouble-shooting Department of Cytogenetics of Wikiversity
Sources: en.wikipedia.org
=== Sovereignty === Favored distribution of vaccines within one or a few select countries, called "vaccine sovereignty", is a criticism of some of the vaccine development partnerships, such as for the AstraZeneca-University of Oxford vaccine candidate, concerning whether there may be prioritized distribution first within the UK and to the "highest bidder" – the United States, which made an advance payment of US$1.2 billion to secure 300 million vaccine doses for Americans, even before the AstraZeneca-Oxford vaccine or a Sanofi vaccine was proved safe or effective. Concerns exist about whether some countries producing vaccines may impose protectionist controls by export restrictions that would stockpile a COVID‑19 vaccine for their own population. The Chinese government pledged in May 2020, that a successful Chinese vaccine would become a "global, public good", implying enough doses would be manufactured for both national and global distribution. Unlike mRNA vaccines, which have to be stored at subzero temperatures, inactivated vaccines from Sinovac and Sinopharm require ordinary refrigeration and may have more appeal in developing countries. In November 2021, the Chinese government pledged to donate in 2022 a further 600 million vaccine doses to Africa, and supply another 400 million through other routes including production by Chinese companies in Africa.
=== Evolution of mental illness representation in film === An overused trope used in film and television is depicting villains or murderers as mentally ill. This trope has evolved throughout the history of filmmaking and cinema. First introduced in the early 1900s, films like Dr. Mabuse, the Gambler (1922) and The Black Cat (1934) depicted the mentally ill villains as mad, evil doctors. Then, with the rise of Alfred Hitchcock films, he introduced the serial killer in Psycho (1960), whose character trope was subsequently used in films like Homicidal (1961), Maniac (1963), Paranoiac (1963), and Nightmare (1963). The 1970s and 1980s brought the popular "slasher" film genre, introducing iconic horror characters such as Michael Myers, Jason, and Freddy Kruger from the franchises Halloween, Friday the 13th, and A Nightmare on Elm Street, respectively.
=== Total bilirubin === Total bilirubin = direct bilirubin + indirect bilirubin Elevation of both alanine aminotransferase (ALT) and bilirubin is more indicative of serious liver injury than is elevation in ALT alone, as postulated in Hy's law that elucidates the relation between the lab test results and drug-induced liver injury
The monoisotopic mass is the sum of the masses of the atoms in a molecule using the unbound, ground-state, rest mass of the principal (most abundant) isotope for each element. The monoisotopic mass of a molecule or ion is the exact mass obtained using the principal isotopes. Monoisotopic mass is typically expressed in daltons (Da). This is also known as the exact (a.k.a theoretical) mass. For typical organic compounds, where the monoisotopic mass is most commonly used, this also results in the lightest isotope being selected. For some heavier atoms such as iron and argon the principal isotope is not the lightest isotope. The mass spectrum peak corresponding to the monoisotopic mass is often not observed for large molecules, but can be determined from the isotopic distribution.
== History == SDA was first mentioned in the scientific literature by 2013, but was only conceptually described at this time. Subsequently, its synthesis and preclinical pharmacology were described by Nina Kastner and colleagues including Matthias Grill at MiHKAL in 2025. Prodrugs of SDA and/or related compounds have also been described.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.